High Cancer Burden Shifted From Urban to Rural Areas and Gap Widening
cancer - Two American Cancer Society studies highlight increase in cancer burden in rural areas
AI Summary: Recent analyses show the colorectal cancer burden has moved increasingly from urban centers to rural areas, widening disparities. Researchers attribute the shift to screening shortfalls, limited access to specialty care and socioeconomic barriers, and call for targeted screening, resource reallocation and tailored prevention efforts as rural populations face rising incidence and poorer outcomes.
- Clinical trials and treatment advances (6)
- Early-onset, prevention, and genetics (5)
- Rural burden and access disparities (8)
- All Other Stories
Clinical trials and treatment advances
Early-onset, prevention, and genetics
Rural burden and access disparities
All Other Stories
A blood test may tailor breast cancer treatment for older women
medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
- EBCC15: Less overtreatment through personalized radiotherapy and surveillance (4)
- Liquid biopsies and sensors advancing cancer detection beyond breast (4)
- Other: biology and global burden stories (3)
- Ultrasensitive ctDNA: tailoring breast cancer care for older patients (5)
- All Other Stories
EBCC15: Less overtreatment through personalized radiotherapy and surveillance
Liquid biopsies and sensors advancing cancer detection beyond breast
Other: biology and global burden stories
Ultrasensitive ctDNA: tailoring breast cancer care for older patients
All Other Stories
Vivek Subbiah: New Nature Study on Thymic Health and Response
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]
AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.
- Aging immunity: why older immune systems fail us (5)
- Front lines: new targets and tactics in cancer immunotherapy (9)
- On the ground: adult thymus drives longevity and therapy success (5)
- All Other Stories
Aging immunity: why older immune systems fail us
Front lines: new targets and tactics in cancer immunotherapy
On the ground: adult thymus drives longevity and therapy success
All Other Stories
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.
A liquid biopsy blood test may improve children's survival of cancer in Africa
medicalxpress - In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt l…
AI Summary: A blood‑based liquid biopsy for EBV‑positive Burkitt’s lymphoma shows promise for earlier, less invasive diagnosis in endemic regions, potentially improving pediatric survival where tissue biopsies are scarce. Early data indicate actionable sensitivity and feasibility for low‑resource settings, offering a scalable path to faster treatment.
Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center
oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]
AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.
New EPA rule could loosen limits on medical device sterilization gas emissions
medicalxpress - The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.
AI Summary: The Environmental Protection Agency proposed easing limits on ethylene oxide — the gas hospitals use to sterilize medical devices — arguing the change protects the medical supply chain. Public‑health experts and community advocates warn long‑term exposure raises cancer risks and say rolling back 2024 safeguards could shift the burden onto nearby residents.
Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.
A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
- HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer (3)
- New insights into why aggressive breast cancers grow and spread (3)
- OTHER: related cancer research and approvals outside this TNBC angle (5)
- All Other Stories
HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer
New insights into why aggressive breast cancers grow and spread
OTHER: related cancer research and approvals outside this TNBC angle
All Other Stories
Roche’s big hope breast cancer drug fails in crucial first-line trial
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.
Fitch upgrades UCHealth’s rating to ‘AA+’
Andrew Cass / beckershospitalreview - Aurora, Colo.-based UCHealth’s credit rating was upgraded to “AA+” from “AA” by Fitch. The upgrade reflects the health system’s very strong financial profile, benefiting from its market position in a growing service area and a long track record of robust …
AI Summary: A large NHS evaluation found that an AI system can detect more invasive breast cancers than traditional reading alone, boosting detection by roughly 10%. The technology matched or rivaled radiologists in a major screening dataset, prompting debate about integration, workflow changes, and careful real-world rollout rather than unleashing bots in mammography rooms immediately.
- Mixed trial findings: AI triage not always noninferior. (1)
- NHS trial: AI boosts breast cancer detection by ~10%. (2)
- OTHER: AI in broader cardiac, hematology, imaging, and finance news. (4)
- Researchers and conferences push AI discussion in breast imaging. (2)
- All Other Stories
Mixed trial findings: AI triage not always noninferior.
NHS trial: AI boosts breast cancer detection by ~10%.
OTHER: AI in broader cardiac, hematology, imaging, and finance news.
Researchers and conferences push AI discussion in breast imaging.
All Other Stories
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
AI Summary: A global phase 3 trial shows romiplostim markedly reduces chemotherapy‑induced thrombocytopenia, cutting severe low‑platelet events and helping patients stay on planned treatment schedules. The finding promises to lower bleeding risk and avoid dose delays, a relief for clinicians and patients alike — and for anyone tired of rescheduled infusions.
Personalized Support Program Improves Smoking Cessation for Cervical Cancer Survivors – UCLA Health
oncodaily - UCLA study shows program doubles quit rates for women and offers a cost-effective approach A new study led by UCLA researchers suggests that a personalized counseling program can significantly help […]
AI Summary: A UCLA-led trial found that a tailored support program for women treated for cervical precancer significantly doubled smoking-cessation rates versus usual care. The intervention combined individualized counseling, follow-up, and survivor-focused resources, proving both clinically impactful and cost-effective — because apparently telling people to “just quit” still isn’t working.
Grail names new CEO as Bob Ragusa retires
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.
Severe COVID or Severe Flu May Raise Risk of Lung Cancer, But Vaccines Helped in Animal Tests
discovermagazine - Learn how severe respiratory illness leaves the lungs vulnerable to cancer, and how vaccines could prevent these vulnerabilities.
AI Summary: New animal and observational evidence suggests severe respiratory infections—including serious COVID‑19 and influenza—can prime lung tissue and accelerate cancer development months to years later. Vaccination appeared to blunt those effects in experimental models, highlighting prevention as a potential cancer‑risk reduction strategy and urging clinicians to watch survivors of severe infections more closely.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.